Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
Franco M. Muggia(NYU Langone Health), Claire F. Verschraegen(The Ohio State University), Leonard Liebes(New York University), Susanne Blank(Heidelberg University), Teresa Rutledge(University of New Mexico), David A. Fishman(New York Hospital Queens), Carolyn Y. Muller(University of New Mexico), Bhavana Pothuri(Gynecologic Oncology Group), Andrea Downey(University of New Mexico), Leslie R. Boyd(University of New Mexico)
Cited by 10
Related Papers
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
|Nature Medicine|2004|517
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|381
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
|Journal of Clinical Oncology|2020|318
Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles
|Cancer Research|2004|246
Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
|Clinical Cancer Research|2012|225